High-mobility Group B1 (HMGB1) and Receptor for Advanced Glycation End-products (RAGE) Expression in Canine Lymphoma

被引：1
|
作者：
Sterenczak, Katharina A. [1 ,2 ,3 ]
Joetzke, Alexa E. [1 ,2 ]
Willenbrock, Saskia [1 ,2 ,3 ]
Eberle, Nina [1 ,2 ]
Lange, Sandra [4 ]
Junghanss, Christian [4 ]
Nolte, Ingo [1 ,2 ]
Bullerdiek, Joern [1 ,2 ,3 ]
Simon, Daniela [1 ,2 ]
Escobar, Hugo Murua [1 ,2 ]
机构：
[1] Univ Vet Med Hannover, Small Anim Clin, D-30559 Hannover, Germany
[2] Univ Vet Med Hannover, German Res Fdn SFB Transregio 37, D-30559 Hannover, Germany
[3] Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany
[4] Univ Rostock, Div Med, Dept Haematol Oncol, D-18057 Rostock, Germany
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 12期
关键词：
Canine lymphoma; HMGB1; RAGE; ENDOTHELIAL GROWTH-FACTOR; NON-HODGKIN-LYMPHOMA; BONE-MARROW ANGIOGENESIS; TOLL-LIKE RECEPTORS; TUMOR ANGIOGENESIS; PROGNOSTIC VALUE; LEUKEMIA; MYELOFIBROSIS; PROTEINS; SPECTRUM;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Canine lymphoma is a commonly occurring, spontaneously developing neoplasia similar to human non-Hodgkin's lymphoma and, thus, is used as a valuable model for human malignancy. HMGB1 and RAGE are strongly associated with tumour progression and vascularisation. Consequently, deregulated RAGE and HMGB1 may play an important role in the mechanisms involved in lymphoma progression. Materials and Methods: Expression patterns of HMGB1 and RAGE were analysed in 22 canine lymphoma and three canine non-neoplastic control samples via real time PCR and canine beta-glucuronidase gene (GUSB) as endogenous control. Results: HMGB1 was up-regulated in the neoplastic samples, while RAGE expression remained inconspicuous. Conclusion: This study demonstrated similar mechanisms in lymphoma progression in humans and dogs due to overexpression of HMGB1, which was described in human lymphomas. RAGE remained stable in terms of expression indicating that the extracellular HMGB1-induced effects are regulated by HMGB1 itself
引用
收藏
页码：5043 / 5048
页数：6
相关论文
共 50 条
  • [41] Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review
    Nguyen, Austin
    Bhavsar, Sheila
    Riley, Erinn
    Caponetti, Gabriel
    Agrawal, Devendra
    INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2016, 20 (04) : 382 - 389
  • [42] Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis
    Qing, Yu-Feng
    Zhang, Quan-Bo
    Pan, Shu-Yue
    Zhou, Jingguo
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome
    Nakamura, Tsukasa
    Sato, Eiichi
    Fujiwara, Nobuharu
    Kawagoe, Yasuhiro
    Maeda, Sayaka
    Yamagishi, Sho-ichi
    CLINICAL BIOCHEMISTRY, 2011, 44 (8-9) : 601 - 604
  • [44] High-mobility group box 1 and the receptor for advanced glycation end products contribute to lung injury during Staphylococcus aureus pneumonia
    Ahmed Achouiti
    Anne Jan van der Meer
    Sandrine Florquin
    Huan Yang
    Kevin J Tracey
    Cornelis van ’t Veer
    Alex F de Vos
    Tom van der Poll
    Critical Care, 17
  • [45] From Hman Megakaryocytes to Patelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation end Products Axis
    Mardente, Stefania
    Mari, Emanuela
    Massimi, Isabella
    Tafani, Marco
    Guerriero, Raffaella
    Morsilli, Ornella
    Pulcinelli, Fabio M.
    Bianchi, Marco E.
    Zicari, Alessandra
    FRONTIERS IN IMMUNOLOGY, 2018, 8
  • [46] High-mobility group box 1 and the receptor for advanced glycation end products contribute to lung injury during Staphylococcus aureus pneumonia
    Achouiti, Ahmed
    van der Meer, Anne Jan
    Florquin, Sandrine
    Yang, Huan
    Tracey, Kevin J.
    van 't Veer, Cornelis
    de Vos, Alex F.
    van der Poll, Tom
    CRITICAL CARE, 2013, 17 (06)
  • [47] Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses
    Tamada, Kenya
    Nakajima, Shingo
    Ogawa, Natsumi
    Inada, Mana
    Shibasaki, Hiroyuki
    Sato, Akira
    Takasawa, Ryoko
    Yoshimori, Atsushi
    Suzuki, Yusuke
    Watanabe, Nobuo
    Oyama, Takahiro
    Abe, Hideaki
    Inoue, Shigeaki
    Abe, Takehiko
    Yokomizo, Takehiko
    Tanuma, S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 511 (03) : 665 - 670
  • [48] Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells
    R Guzmán-Ruiz
    F Ortega
    A Rodríguez
    R Vázquez-Martínez
    A Díaz-Ruiz
    S Garcia-Navarro
    M Giralt
    A Garcia-Rios
    D Cobo-Padilla
    F J Tinahones
    J López-Miranda
    F Villarroya
    G Frühbeck
    J M Fernández-Real
    M M Malagón
    International Journal of Obesity, 2014, 38 : 1545 - 1554
  • [49] Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells
    Guzman-Ruiz, R.
    Ortega, F.
    Rodriguez, A.
    Vazquez-Martinez, R.
    Diaz-Ruiz, A.
    Garcia-Navarro, S.
    Giralt, M.
    Garcia-Rios, A.
    Cobo-Padilla, D.
    Tinahones, F. J.
    Lopez-Miranda, J.
    Villarroya, F.
    Fruehbeck, G.
    Fernandez-Real, J. M.
    Malagon, M. M.
    INTERNATIONAL JOURNAL OF OBESITY, 2014, 38 (12) : 1545 - 1554
  • [50] Structural insight into the ligand-receptor interaction between glycyrrhetinic acid (GA) and the high-mobility group protein B1 (HMGB1)-DNA complex
    Yamaguchi, Hideaki
    Kidachi, Yumi
    Kamiie, Katsuyoshi
    Noshita, Toshiro
    Umetsu, Hironori
    BIOINFORMATION, 2012, 8 (23) : 1147 - 1153
12345